Overview

Gender

male

George Demetri, M.D., is a clinical advisor of Blueprint Medicine. Dr. Demetri received an undergraduate degree in biochemistry from Harvard University, followed by a Research Fellowship at the Université de Besancon, France, after which he received his medical degree from Stanford University School of Medicine.

After completing an internal medicine residency and chief residency at the University of Washington Hospitals in Seattle, he completed the fellowship in Medical Oncology at the Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, where he has served as an attending physician since 1989.

Dr. Demetri and the multidisciplinary team at Dana-Farber/Harvard Cancer Center have developed one of the largest centers of excellence for research and care of sarcoma patients, focusing on the development of novel therapies, enabled by directing the Ludwig Center at Dana-Farber Harvard and the Center for Novel Experimental Therapeutics at Dana-Farber.

Dr. Demetri’s research and clinical interests have centered on mechanism-based drug development for solid tumors, with a particular emphasis on molecularly-defined subsets of sarcomas such as gastrointestinal stromal tumours (GIST). Dr. Demetri has contributed to the development of several new drugs for sarcomas and other malignancies, including imatinib, sunitinib, dasatinib, trabectedin, vemurafenib, everolimus, pazopanib, regorafenib and other new targeted therapies in development.

Dr. Demetri serves as chair of the medical advisory board for the Sarcoma Foundation of America as well as several scientific and editorial advisory boards. With an interest in internet-based patient support, he also serves on the Medical Advisory Board of ASCO’s CancerNet as well as CancerCommons.org.